Journal of Global Pharma Technology
Pfizer goes to court to protect exclusive rights to sell Viagra
Patent protection and product pipelines are top priorities for every pharmaceutical manufacturer, which is why Pfizer Inc. and Teva Pharmaceuticals International Ltd. will be in federal court in Norfolk, Va., starting Wednesday as Pfizer fights to keep exclusive rights to Viagra through 2019. Synageva BioPharma has entered into a merger agreement with Trimeris, under which Synageva will merge with Trimeris in an all-stock transaction. Upon completion of the merger, Trimeris will issue to Synageva stockholders shares of Trimeris common stock such that Synageva stockholders will own 75% of the combined company's shares and Trimeris stockholders will own 25%.The combined company will be named as Synageva BioPharma and will operate under the leadership of the Synageva management team with president and CEO Sanj Patel. (Source:http://drugdiscovery.pharmaceutical-business-review.com) Sun Pharma announces USFDA approval for DOCEFREZTM
(docetaxel) for Injection
Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary an approval for its New Drug Application (NDA) for DOCEFREZTM (docetaxel) for Injection, 20 mg/vial and 80 mg/vial. Impax gets FDA warning letter for plant issues
Impax Laboratories Inc. received a U.S. Food and Drug Administration warning letter related to its Hayward, Calif., manufacturing facility that led to the voluntary recall of its generic cholesterol drug, fenofibrate. The pharmaceutical company said the inspection, conducted between Dec. 13, 2010 and Jan. 21, 2011 cited issues related to sampling and testing of in- process materials and drug products, production record review and the process for investigating the failure of certain manufacturing batches. Prolor reports positive preclinical trial results for obesity drug
results from a comparative animal study of its long-acting anti-obesity drug candidate oxyntomodulin (OXY-RPEG). The study compared the weight loss and reduction in food intake by animals who received one or two weekly injections of OXY-RPEG with animals who received two daily injections. Animals injected once or twice a week demonstrated significantly higher weight loss, reduction of food intake, and duration of weight loss compared with animals who received two injections a day. Lincoln Pharmaceuticals Limited (LPL) has recorded total revenue of Rs 189.73 crore in March 2011, an increase of 49.72 per cent over Rs 126.72 crore in the previous year for the fiscal year. Claris Life Sciences Limited, one of the largest sterile injectables pharmaceutical companies in India, announced on Wednesday that it has received an in-principle approval for its drug-Propofol- in the European Cipla introduces new pain free screening technology for early
detection of breast cancer in India - ‘No Touch Breast Scan’

Cipla, one of the leading pharmaceutical companies from India, today
announces the launch of a breakthrough screening technology in India today called the ‘No Touch Breast Scan (NTBS); ' the first-ever
painless, non-invasive and radiation-free breast scanning technique for detecting breast cancer at an early stage. Welcoming the introduction of NTBS in India, Dr. Rakesh Sinha, Consultant Gynaecologist Surgeon, BEAMS Hospital , Mumbai said, “The No-Touch Breast scan is a painless option for women who wish to get themselves regularly screened. It is of particular use in younger women who have dense breasts and mammography is inconclusive. If a woman shows changes on the NTBS then she is sent for further investigation which includes mammography, sonography etc. At BEAMS Mumbai, of the 41 patients who have undergone the NTBS test, only 1 had to be referred for mammography.” Ziopharm plans early trials of new cancer drug
Ziopharm Oncology Inc. said that the Food and Drug Administration will allow it to conduct human testing of an experimental melanoma drug. The company said the FDA accepted its application for the drug. It designated the product ZIN ATI-001 and said it plans to start an early-stage clinical trial to evaluate its safety and its effects. Ziopharm said new preclinical studies indicate the new drug candidate works similarly to a DNA drug in early-stage testing. ZIN ATI-001 is being developed as part of a partnership between Ziopharm and Intrexon Corp. Novartis Bexsero Vaccine Encourages
Novartis - recently presented data from some
studies, which showed that its pipeline candidate Bexsero vaccine induces robust immune response in infants, toddlers and adolescents suffering from Meningococcal serogroup B (MenB) disease. The vaccine, thus has the potential to provide broad usage. The vaccine is also known as 4CMenB. The data were presented at The European Society for Paediatric

Source: http://www.jgpt.co.in/PHARMANEWS.pdf


MATERIAL SAFETY DATA SHEET LOSP Treated Timber STATEMENT OF HAZARDOUS NATURE Not hazardous according to criteria of Worksafe Australia. COMPANY DETAILS IDENTIFICATION LOSP TREATED TIMBER LOSP treatment is used to protect timber from attack by termites, insectsand fungal decay. The treated timber is used for exterior building andstructural applications in above ground situation

Us forum connection #82, october 2010

US FORUM CONNECTION #82, OCTOBER 2010 This free newsletter is sponsored by the United States Forum of The Delta Kappa Gamma Society International. The Delta Kappa Gamma Society International is an organization of leading women educators with over 100,000 members. Delta Kappa Gamma members wishing to subscribe to this FREE newsletter should send a request to e urge you to share this newsle

Copyright © 2010-2014 Drug Shortages pdf